The Chemical Information & Computer Applications Group (CICAG) and Biological & Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry are once again organising a conference to present the current advances in AI and machine learning in Chemistry.
The joint ISSX/JSSX meeting is for researchers looking to gain a deeper understanding of drug metabolism and pharmacokinetics.
Join Optibrium during a full program of summer events showcasing our Cerella platform.
Join Daniel Barr to hear more about how deep learning imputation prioritises the most relevant data, accounts for uncertainty, and guides experiment selection to bring additional value to small molecule discovery.
Join Optibrium’s Chris Khoury at the 38th NMCS meeting in Seattle, 23-26 June
Join Optibrium at HubXchange in Boston to hear more about implementing AI in drug discovery.
CAMBRIDGE, UK and CAMBRIDGE, US 14 May 2024 – Optibrium, a leading developer of software and AI solutions for drug…
Peer-reviewed study published in Xenobiotica describes an innovative new method that predicts the routes and products of Phase I and II metabolism with high sensitivity and greater precision than
other approaches
Cloud-based version of StarDrop retains all the functionality and interactivity of desktop version with improved accessibility and lower total cost of ownership for customers.
Backed by six years’ research, the new StarDrop Metabolism module combines quantum mechanics and machine learning to better predict the metabolic fate of drug candidates.
CAMBRIDGE, UK and BOSTON, USA, 15 March 2023 – Optibrium, a leading developer of software and AI for small molecule…
New role will lead technology development as the Company continues to scale team and global business operations. Appointment of former Merck, Sharp and Dohme (MSD) Director of R&D Analytics supports continued innovation of Optibrium’s AI drug discovery software.
Establishment of Optibrium Inc. bolsters ongoing strategic Company growth and strenghtens direct US customer support. Dr Tamsin Mansley promoted to President of Optibrium Inc. to lead growing US-based team and business operations.
Michelle Harrison appointed as Head of Strategic Marketing; Chris Khoury and Imran Ghauri join to boost Optibrium’s business development team. UK and US-based appointments with proven AI and life science expertise will support the next phase of commercial growth for Optibrium’s computational drug discovery technologies.
Second round of funding from existing investors will further drive company expansion and commercial growth of its AI-enabled drug discovery technology.
Innovative predictive methods support virtual screening and compound design in the absence of 3D structure data.
